# Roche agrees to buy 89bio for up to $3.5B to gain pegozafermin, a phase 3 MASH drug

Canonical page: https://technooptimist.io/stories/roche-agrees-to-buy-89bio-for-up-to-3-5b-to-gain-pegozafermin-a-phase-3-5a3068b0
Date: 18 Sep 2025
About: [Roche](https://technooptimist.io/companies/roche.md) · [Pegozafermin](https://technooptimist.io/biotech/pegozafermin.md)
Original source: https://www.roche.com/media/releases/med-cor-2025-09-18

Roche agreed to acquire 89bio for $14.50 per share in cash (about $2.4B) plus a contingent value right of up to $6 per share, for up to $3.5B in total. The prize is pegozafermin, a long-acting FGF21 hormone analog in phase 3 for MASH with moderate to severe fibrosis and compensated cirrhosis. Roche sees it as a partner for its incretin obesity drugs.

## Key facts

- CVR: $2.00 for a cirrhosis launch by Mar 2030; $1.50 at $3B annual sales by 2033; $2.50 at $4B by 2035.
- About 52% premium to 89bio's 60-day average price.
- Also in development for severe hypertriglyceridemia.

---

The Techno Optimist tracks every frontier of technology, program by program: https://technooptimist.io/ (a Markdown version of any page: add .md to its URL; site map for agents: https://technooptimist.io/llms.txt).
Data API (JSON, realtime stream): https://technooptimist.io/developers. People read 5 pages free, then Reader $10/month; these Markdown pages are open to agents.